Levopropoxyphene
| Names | |
|---|---|
| Preferred IUPAC name
(2R,3S)-4-(Dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl propanoate | |
| Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
| Properties | |
Chemical formula
|
C22H29NO2 |
| Molar mass | 339.471 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Levopropoxyphene is an antitussive. It is an optical isomer of dextropropoxyphene. The racemic mixture is called propoxyphene. Only the dextro-isomer (dextropropoxyphene) has an analgesic effect; the levo-isomer appears to exert only an antitussive effect. It was formerly marketed in the U.S. by Eli Lilly under the tradename Novrad (a reversal of Darvon) as an antitussive.[1][2] Unlike many antitussives, it binds poorly to the sigma-1 receptor.[3]
- ^ Reference.MD: Propoxyphene napsylate
- ^ Lutje Spelberg, Jeffrey Harald (2003). Enantioselective biocatalytic conversions of epoxides. Rijksuniversiteit Groningen.
- ^ Klein M, Musacchio JM (October 10, 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–156. doi:10.1007/BF00711241. PMC 11567495. PMID 3044591. S2CID 33844132.